RWhat the company does: Rentschler Biopharma provides contract development and manufacturing services for biopharmaceuticals, helping other pharmaceutical companies develop and produce complex medicines. How its products work: It offers end-to-end services in biopharma development and manufacturing, backed by facilities and staff that design, optimize, and produce biologic drugs at scale for clients, including a major site in Milford, MA that has expanded capacity to serve the international market. How it differs from competitors: It has a long heritage in biopharma, a dedicated CDMO focus since 1997, and a global footprint with a major U.S. site and expanded capacity, positioning itself as a reliable partner for developing and manufacturing complex biologics. What its goal is: To be a trusted partner for pharmaceutical companies by providing development and manufacturing services at scale, supporting clients as they bring biologic medicines to market.
Work here?Claim your company
Industries
Company Size
501-1,000
Company Stage
Series A
Total Funding
$1.6M
Headquarters
Laupheim, Germany
Founded
1927
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Total Funding
$1.6M
Below
Industry Average
Funded Over
1 Rounds
Industry standards
Rentschler Biopharma receives the Business Medal of the State of Baden-Wuerttemberg. Location Laupheim, Germany Published on Friday, November 6, 2026 * Prestigious award recognizes Rentschler Biopharma's entrepreneurial achievements and contribution to Baden-Wuerttemberg's economy * Minister of Economic Affairs Dr. Nicole Hoffmeister-Kraut presented the medal at an awards ceremony on November 5, 2026 * Honor underscores the company's longstanding ties to Laupheim and its importance to the international biopharmaceutical industry Rentschler Biopharma SE, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, has been awarded the Business Medal of the State of Baden-Wuerttemberg. The award was presented by Dr. Nicole Hoffmeister-Kraut, Minister of Economic Affairs, Labor and Tourism. The distinction recognizes outstanding entrepreneurial achievements and exceptional contributions to Baden-Wuerttemberg's economy. Dr. Torsten Woehr, Chief Executive Officer (CEO) accepted the award on behalf of the company. In her laudatory remarks, Dr. Nicole Hoffmeister-Kraut highlighted Rentschler Biopharma's foresight, its importance to the region, and its commitment to combining economic success with social responsibility: "Today, the company looks back on more than 150 years of history and has become a leading specialist in the development and manufacturing of biopharmaceuticals." Addressing the 14 individuals and companies honored, the Minister added: "You are an impressive testament to the strength and diversity of Baden-Wuerttemberg's economy and its future readiness. Dr. Torsten Woehr, CEO of Rentschler Biopharma, commented: "The Business Medal is a special honor for Rentschler Biopharma. Above all, I see it as recognition for the people who have shaped and advanced our company over many years. Their expertise, dedication, and reliability are the foundation of our success and our long-standing partnerships with our clients. Together with our employees, we are proud to contribute to the global supply of life-saving biopharmaceuticals." The Business Medal of the State of Baden-Wuerttemberg has been awarded since 1987 to individuals and companies that have made outstanding contributions to the state's economy. As an independent family-owned company with deep roots in Laupheim, Rentschler Biopharma has evolved into a global biopharmaceutical CDMO. Today, the company supports pharmaceutical and biotechnology companies in translating innovative ideas into life-saving biopharmaceuticals, guiding complex biopharmaceutical programs from process development through commercial supply. These therapies address a wide range of diseases, including serious and rare conditions such as cancer, autoimmune diseases, hereditary disorders, and cardiovascular diseases. Rentschler Biopharma combines decades of experience and expertise with a commitment to high-quality standards and reliable execution. Rentschler Biopharma continues to invest strategically in infrastructure and technologies to support the long-term development of its sites. A recent example is the new buffer media station in Laupheim, representing the company's largest single investment in Germany to date. Covering 3,400 square meters, the facility will provide additional capacity for the production of buffer and media solutions, along with modern infrastructure designed to meet stringent quality standards. Completion and operational launch are scheduled for the end of 2027, with full utilization to be realized by 2028. The new infrastructure will thus provide an important foundation for further sustainable growth at the Laupheim site. The award underscores Rentschler Biopharma's strong ties to Baden-Wuerttemberg and its commitment to the region's long-term economic strength. The company remains guided by its vision: Advancing medicine to save lives. Together.
Two Worcester County firms part of $40M Life Sciences awards. By Tom Marino | September 29, 2026 Last Updated: September 29, 2026 WORCESTER - Two Worcester County companies were among 38 life sciences firms statewide sharing nearly $40 million in tax incentives Gov. Maura Healey announced Tuesday, Sept. 22, a round expected to create 1,644 jobs across Massachusetts. * Eyepoint Inc., which is expanding in Northbridge, received $1,000,000 tied to a commitment of 40 new jobs. * Rentschler Biopharma Inc., expanding in Milford, received $517,500 for 23 jobs. Healey announced the full round of awards at SMC Ltd.'s facility in Devens, alongside Economic Development Secretary Eric Paley and Massachusetts Life Sciences Center Interim CEO Liz Graham. The awards were made through the center's Tax Incentive Program, which supports companies expanding research, development and manufacturing operations in the state. Of the 38 companies receiving awards, 31 are expanding outside Boston and Cambridge and account for 71% of the new jobs expected from this round, according to the state. "Massachusetts leads the world in life sciences because we invest in the people and companies that are creating the jobs, treatments and technologies of the future," Healey said in a statement. Since the Massachusetts Life Sciences Center was established, companies participating in the tax incentive program have committed to creating more than 22,300 jobs, according to the state. In November 2024, Healey signed the Mass Leads Act, which raised the statutory cap on the program from $30 million to $40 million and made other changes intended to strengthen it. Recipients are required to maintain their job commitments over a three-year period and must file regular reports documenting jobs created. The program is jointly administered by the Massachusetts Life Sciences Center and the Massachusetts Department of Revenue, which handles its technical administration. The remaining 36 companies receiving awards in this round, all outside Worcester County, are listed below. | Company | Location | Incentive | Jobs | | Alloy Therapeutics Inc. Waltham | $180,000 | 10 | | Ardelyx Inc. Waltham | $277,500 | 15 | | AstraZeneca Pharmaceuticals LP | Cambridge | $900,000 | 50 | | Bristol-Myers Squibb Company | Devens | $2,875,000 | 125 | | CBSET Inc. Lexington | $660,000 | 33 | | Cogent Biosciences Inc. Waltham | $360,000 | 20 | | Dash Bio Inc. Waltham | $285,000 | 12 | | Dyne Therapeutics Inc. Waltham | $937,500 | 50 | | Gentuity LLC | Sudbury | $276,000 | 15 | | Insulet Corporation | Acton | $10,000,000 | 250 | | IPG Medical Corporation | Marlborough | $195,000 | 10 | | Kailera Therapeutics Inc. Waltham | $900,000 | 50 | | KalVista Pharmaceuticals Inc. Framingham | $324,000 | 18 | | Kymera Therapeutics Inc. Watertown | $630,000 | 35 | | Lexington Medical Inc. Bedford | $180,000 | 10 | | Lila Sciences Inc. Cambridge | $3,600,000 | 200 | | Madrigal Pharmaceuticals Inc. Waltham | $900,000 | 50 | | Mercy BioAnalytics Inc. Waltham | $120,000 | 5 | | Monte Rosa Therapeutics Inc. Boston | $720,000 | 40 | | Nanopath Inc. Cambridge | $288,000 | 12 | | Olaris Inc. Framingham | $125,000 | 5 | | Pramand LLC | Burlington | $257,500 | 10 | | Rapport Therapeutics Inc. Boston | $483,000 | 21 | | Repligen Corporation | Marlborough | $415,000 | 20 | | Rhythm Pharmaceuticals Inc. Boston | $462,500 | 25 | | Sanegene Bio USA Inc. Woburn | $235,000 | 10 | | SMC Ltd. Devens | $1,350,000 | 54 | | Spear Bio Inc. Woburn | $235,000 | 10 | | Terrestrial Bio Inc. Woburn | $1,080,000 | 36 | | TransMedics Group Inc. Andover | $1,860,000 | 62 | | Triveni Bio Inc. Watertown | $288,000 | 12 | | Verastem Inc. Needham | $437,000 | 19 | | Vericel Corporation | Burlington | $1,100,000 | 50 | | Vertex Pharmaceuticals Inc. Boston | $3,025,000 | 121 | | Werfen | Bedford | $1,303,500 | 66 | | Zoll Medical Corporation | Chelmsford | $1,100,000 | 50 |
Rentschler Biopharma has appointed Dr Torsten Woehr as chief executive officer, effective 1 August 2026. Woehr brings over 25 years of CDMO experience, most recently serving as chief commercial officer at Bachem Group, where he led global commercial activities driving strategic investments. The German contract development and manufacturing organisation, which employs approximately 1,400 staff across sites in Laupheim and Milford, Massachusetts, says the appointment advances its corporate strategy focused on long-term growth and value creation. Woehr holds a doctorate in bioorganic chemistry from EPFL in Lausanne and has over a decade of US experience. Professor Uwe Buecheler will step down as interim CEO and return to his role as vice chairman of the supervisory board.
Rentschler Biopharma has appointed Dr Veit Bergendahl as chief operating officer and executive board member, effective 1 April 2026. He will oversee process development, clinical and commercial cGMP manufacturing, engineering and technology, and production automation at the German CDMO. Bergendahl brings over 20 years of international experience in biopharmaceutical development and manufacturing. He spent 13 years at Boehringer Ingelheim, most recently as head of clinical supply biologicals, where he oversaw commissioning of the Biologicals Development Centre in Biberach, Germany. He has also held positions at Miltenyi Biotec, Roche Germany and Cellular Dynamics International in the US. He succeeds Christiane Bardroff, who is leaving to pursue opportunities outside the company. Rentschler Biopharma employs approximately 1,400 people across sites in Laupheim, Germany, and Milford, Massachusetts.
Rentschler Biopharma appoints Veit Bergendahl as COO. Veit Bergendahl will assume operational responsibility for process development, clinical and commercial cGMP manufacturing, engineering and technology, as well as automation in production from April 1, 2026. Rentschler Biopharma has appointed Veit Bergendahl as Chief Operating Officer (COO) and member of the Executive Board. He succeeds Christiane Bardroff, who is taking on a new professional challenge outside the company and will leave the company at her own request during the first quarter of this year. As of April 1, 2026, Bergendahl will be responsible for process development, clinical and commercial cGMP manufacturing, engineering and technology, as well as automation at Rentschler Biopharma. Bergendahl brings more than 20 years of international experience in biopharmaceutical development, manufacturing, and CMC. He has worked in Europe and the USA for renowned pharmaceutical and biotech companies, in contract development and for research institutions. He has excellent knowledge of the entire biopharmaceutical value chain - from early development through clinical supply to commercial production, including international regulatory requirements. His expertise includes the management of complex development and manufacturing processes, site development, including overall operational and commercial responsibility, efficiency improvement, and cooperation with international partners. Nikolaus F. Rentschler, Chairman of the Supervisory Board: "I am very pleased that Veit Bergendahl is taking on the role of Chief Operating Officer as the company enters a phase of further accelerated growth. With his strategic understanding of the biopharmaceutical value chain, his outstanding industry expertise, and many years of international experience in leadership roles, he will make a significant contribution to further strengthening our culture of reliability in a highly demanding market environment. His shared values and strong focus on partnership and sustainable development represent a significant asset for both our company and our clients." "With Veit Bergendahl, whom I hold in the highest regard, we are gaining a highly experienced international leader who will strengthen our operations with his deep expertise and a clear forward-looking perspective," commented Uwe Buecheler, Interim CEO of Rentschler Biopharma. "His comprehensive understanding of the development, manufacturing, and scaling of complex biopharmaceutical products is combined with a strong client focus and the highest commitment to quality. I particularly value his ability to link operational excellence with entrepreneurial thinking, inspiring teams to work toward shared goals. I am convinced that he will further accelerate the positive direction we have taken, especially through his strengths in innovation and operational excellence. I very much look forward to working with him and know that, together with our colleagues in Laupheim and Milford, he will provide important impetus for the continued successful development of Rentschler Biopharma." Veit Bergendahl added: "I am very much looking forward to working with the Executive Board and the team at Rentschler Biopharma. As a family-owned company and leading CDMO, Rentschler Biopharma delivers tailor-made solutions for essential biopharmaceuticals and combines scientific innovation with a strong sense of responsibility toward patients worldwide. It is very important to me to further build on this strong foundation. I aim to support and strengthen the dedicated teams in Laupheim and Milford, further enhance the robustness and efficiency of processes, and leverage new technologies to further advance operational excellence and develop long-term client-partnerships based on the highest levels of quality and reliability." Before joining Rentschler Biopharma, Bergendahl worked at Boehringer Ingelheim for 13 years in various functions with increasing responsibility. Most recently, as Head of Clinical Supply Biologicals, he was responsible for the commissioning and go-live of the Biologicals Development Center at the research and development site in Biberach, and since 2023, he has been in charge of the single-use facility for clinical production with 2x2,000L bioreactors. Previously, as Executive Director Upstream Manufacturing, he managed a large-scale production facility (10x15,000L). Previous positions at Boehringer ranged from managing transfer projects in clinical phase I to commercial processes in contract manufacturing. His other professional stations were at Miltenyi Biotec and Roche (Germany). In the USA, he conducted research at the University of Wisconsin and held management positions at Cellular Dynamics International. Bergendahl holds a degree in biochemistry and a doctorate in biology from Philipps University, Marburg. Company. Erwin-Rentschler-Str. 21 88471 Laupheim Germany
Find jobs on Simplify and start your career today
Don't see your dream role? Check out thousands of other roles on Simplify.Browse all jobs
Industries
Company Size
501-1,000
Company Stage
Series A
Total Funding
$1.6M
Headquarters
Laupheim, Germany
Founded
1927
Find jobs on Simplify and start your career today
Don't see your dream role? Check out thousands of other roles on Simplify.Browse all jobs